Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lessened its stake in shares of Ikena Oncology, Inc. (NASDAQ:IKNA) by 8.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 388,748 shares of the company’s stock after selling 35,629 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.81% of Ikena Oncology worth $673,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Vanguard Personalized Indexing Management LLC purchased a new stake in Ikena Oncology in the second quarter valued at $30,000. BBR Partners LLC purchased a new stake in shares of Ikena Oncology in the 2nd quarter valued at about $33,000. AQR Capital Management LLC acquired a new stake in shares of Ikena Oncology in the second quarter valued at approximately $36,000. FMR LLC grew its position in Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after purchasing an additional 18,607 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ikena Oncology in the second quarter valued at about $75,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

Ikena Oncology Price Performance

Ikena Oncology stock opened at $1.67 on Tuesday. The stock’s 50 day moving average price is $1.71 and its 200 day moving average price is $1.69. The company has a market cap of $80.59 million, a PE ratio of -1.36 and a beta of 0.49. Ikena Oncology, Inc. has a 1-year low of $1.22 and a 1-year high of $2.32.

Ikena Oncology (NASDAQ:IKNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.08. On average, equities research analysts anticipate that Ikena Oncology, Inc. will post -0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Wedbush restated a “neutral” rating and issued a $2.00 price target on shares of Ikena Oncology in a research report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Ikena Oncology in a report on Monday, November 11th.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.